APVO.US Aptevo Therapeutics Inc

Healthcare Biotechnology USA Stocks
0.5941 USD
Close of Nov 14, 2026
0.5940 25.65
Market cap
USD 2.91M
P/E
0.0x
P/B
0.23x
ROE
-432.1%
Dividend yield
54.06%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is APVO.US undervalued?

Graham number

The Graham number of Aptevo Therapeutics Inc cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Aptevo Therapeutics Inc fundamental analysis

No fundamental analysis for Aptevo Therapeutics Inc yet.

Aptevo Therapeutics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Aptevo Therapeutics Inc

Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. Its lead clinical blood cancer candidate is mipleta…

Full company profile